In conclusion, even though growing evidence highlights the PI3K/AKT/Foxo axis as an attractive therapeutic target for cancer immunotherapy, one should be cautious when it comes to the specificity, the duration, and the dose–effect of this type of treatment. The gene discussed is PIK3CD; the disease is cancer.